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Effects of Etanercept Are Distinct from Infliximab in
Modulating Proinflammatory Genes in Activated
Human Leukocytes
Asifa S. Haider1, Irma R. Cardinale1, Julia A. Whynot1 and James G. Krueger1
Proinflammatory diseases like rheumatoid arthritis, Crohn’s disease, and psoriasis have been treated by the
tumor necrosis factor (TNF) antagonists infliximab and etanercept with different degrees of success. Although
these agents are widely used in humans, little is known about their mechanisms of action or why etanercept and
infliximab have differences in clinical activity. In this study, we define leukocyte genes that are suppressed by
etanercept within 24 hours of exposure. Compared to previous work with infliximab, fewer immune-related
genes are suppressed by etanercept. Importantly, the range of genes suppressed by these alternative TNF
inhibitors is only partially overlapping, suggesting each has unique immune modulating effects. In sharp
contrast to etanercept, infliximab strongly suppresses genes associated with ‘‘Type 1’’ immune responses (IFN-g
and the IL-12-receptor beta 2 subunit), providing a clear mechanism for clinically relevant immune suppression.
Journal of Investigative Dermatology Symposium Proceedings (2007) 12, 9–15. doi:10.1038/sj.jidsymp.5650032
INTRODUCTION
Two biologic tumor necrosis factor (TNF) inhibitors, etaner-
cept and infliximab, are effective in treating psoriasis and
psoriatic arthritis (Gottlieb, 2005), but differences exist in the
rapidity of therapeutic improvement, the overall fraction of
patients that respond to the agents, and the range of other
inflammatory diseases, for example, Crohns disease, that can
be effectively treated. Although etanercept and infliximab are
structurally different, that is, etanercept is a TNF-receptor-
immunoglobulin fusion protein (Mohler et al., 1993), and
infliximab is a chimeric antibody specific for TNF (Knight
et al., 1993), each of these molecules can effectively inhibit
TNF-mediated responses in vitro (Scallon et al., 2002).
However, in vivo pharmacologic mechanisms of these
alternative TNF inhibitors are poorly understood, as is the
range of inflammatory genes that may be regulated by these
biologic agents.
In a recent study, we used gene arrays to define a broad set
of genes, which are induced in peripheral blood mono-
nuclear leukocytes through activating T cells with antibodies
to CD3 and CD28 (Haider et al., submitted). In this mixed
cell culture, cytokines produced by activated T-cells (IFN-g,
TNF, and many others) have secondary effects on other cell
types, for example, monocytes, such that an extremely wide
range of cytokine-regulated gene products is induced. By
blocking ‘‘inductive’’ effects of secreted cytokines in these
cultures with monoclonal antibodies, we have been able to
define genes that are selectively regulated by IFN-g or TNF in
leukocytes. To extend this work, we have now studied
the range of genes that are regulated by etanercept in mixed
leukocyte cultures. A relatively small set of genes (n¼29)
was commonly suppressed by etanercept and a TNF antibody
(infliximab), whereas 55 genes were uniquely suppressed
by etanercept versus 513 genes uniquely suppressed
by infliximab. Overall, these results establish distinct biologic
activities of etanercept and infliximab and they suggest a
potential explanation for differences in pharmacologic
activity across the range of diseases treated with these
agents.
RESULTS
Human peripheral blood mononuclear leukocytes were
cultured for 24 hours with bead-bound antibodies to CD3
and CD28 in order to activate T cells. We confirmed
activation of T cells by measuring CD3/CD69þ cells by
flow cytometry. There were 98.6% cells that were activated
in anti-CD3/CD28 costimulated peripheral blood mono-
nuclear cells (PBMCs) as compared to 4.62% of non-
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stimulated PBMCs. In some cultures, etanercept was added
during this activation period. T-cell activation was not
generally suppressed by etanercept, as 491% of T cells
became CD69þ in etanercept-treated cultures. In addition,
we observed no significant increase in apoptosis of T cells
(assessed by Annexin V and propidium-iodide staining) in
etanercept-treated cultures (data not shown).
Abundance of cellular mRNA was quantified by hybridi-
zation of complementary DNA to Affymetrix U95Av2 gene
arrays that contain B12,000 genes. There were 41,700
genes that were significantly upregulated by activation
(Po0.05, after correction for multiple measures). Figure 1
shows heatmaps of genes that are induced in activated
mononuclear leukocytes and also 86 genes whose expression
is significantly suppressed by etanercept treatment (Figure 1,
upper panel; Table 1 for a list of the top 36 genes and
associated P-values). We noted that out of six donors there
were some differences in response to etanercept – two donors
responded more strongly than the other four. Etanercept
downregulated the gene expression in these two donors
down to normal levels as seen by the heatmap tiles in
etanercept-treated versus non-stimulated PBMCs (Figure 1).
Also as shown in Figure 1 (bottom panel), many other
activation-associated genes were not significantly suppressed
by etanercept. For example, CD69 mRNA was upregulated
4.1-fold in CD3/CD28 stimulated cultures and 4.2-fold in
etanercept exposed cultures – similar levels of CD69
were confirmed by measuring protein expression by flow
cytometry.
We detected several proinflammatory genes that were
regulated by etanercept. Etanercept binds equally to TNF and
lymphotoxin alpha (LTA) (Schall et al., 1990). Interestingly,
we detected reduced expression of LTA mRNA in etanercept-
treated cultures (Figure 2). Three chemokines of interest,
XCL1 (SCYC1, SCM1a), XCL2 (SCYC2, SCM1b), and TARC
(CC chemokine 17, thymus and activation-regulated chemo-
kine) and several genes of type 2 pathway like IL-4, -5, and -9
were regulated by etanercept. TARC has been shown to be
regulated by TNF (Sumyoshi et al., 2003) and produced by
monocytes (Imai et al., 1999) that are treated with
granulocyte–macrophage colony-stimulating factor. In our
analysis granulocyte–macrophage colony-stimulating factor
was significantly downregulated by treatment of activated
PBMCs (ACT) with etanercept (ET) (ACT: 34.17710.3, ET:
20.976.0; n¼6. Po0.05). We confirmed the expression of
several type 2 genes IL-4, -5, and -9 and TARC to be
exclusively regulated by etanercept (Table 1). This suggests
that etanercept is affecting the cytokines produced mainly by
Th2 T cells. Infliximab, on the other hand, downregulated
type 1 genes like IFN-g and IL-12-receptor beta 2.
DISCUSSION
This study illustrates a pharmacogenomic approach to
elucidate the effects of etanercept and infliximab in a model
of ‘‘inflammation’’. One finding is the suppressive effect of
etanercept on LTA gene expression. There is not much known
about the pharmacology of LTA; however, there are reports of
association of response to etanercept with genetic variation in
LTA-TNF regions (Criswell et al., 2004). LTA is involved in
the development of follicular dendritic cells and induces
signals that lead to lymphoid neo-organogenesis, phenomena
observed in autoimmune disease like rheumatoid arthritis
(Takemura et al., 2001) and tumors (Criswell et al., 2004).
This suggests that etanercept could suppress lymphoid neo-
organogenesis, which is consistent with reduced numbers of
mature dendritic cells in psoriasis lesions treated for several
months with etanercept (Gottlieb et al., 2005).
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Figure 1. Genes downregulated by etanercept in activated PBMCs. mRNA
from cultured PBMCs was hybridized to individual oligonucleotide arrays
containingB12,000 human genes (Affymetrix HG-U95Av2 chips). Heatmaps
show unsupervised hierarchical clusters of genes regulated by etanercept in
PBMCs using similarity measure: Pearson’s correlation. Gene lists were
created after significance analysis as defined by a paired Welch test, with a
subsequent correction for multiple gene comparisons by the Benjamini and
Hochberg method (Po0.05). The genes regulated by 41.2-fold mean
expression levels are represented with red lines (upregulated) as compared to
green lines (downregulated). Genes in PBMCs activated with anti-CD3/CD28
(ACT) are compared to non-stimulated and activated in the presence of TNF
inhibitor etanercept, n¼6. (a) Heatmap of 86 genes significantly
downregulated by treatment with etanercept. (b) Heatmap representing
41,700 genes upregulated by activation but not affected after treatment with
etanercept. The top 36 genes downregulated by etanercept are listed in Table
S1 available online with a complete list of etanercept-regulated genes, with
fold changes and P-values.
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The two chemokines downregulated by etanercept, XCL1
and XCL2, have been identified as two isoforms of
lymphotactin (Yoshida et al., 1998). They are produced by
CD8þ T cells and natural killer cells and are chemotactic for
lymphocytes and natural killer cells (Maghazachi et al.,
1997). The expression of lymphotactin is upregulated in CD3/
CD28 costimulated T cells in a calcineurin-dependent
manner (Cristillo et al., 2003). Classical anti-psoriasis drugs
Table 1. Activation genes in PBMCs downregulated by etanercept
Activation (ACT) genes
downregulated by
etanercept (ET): fold
change ACT versus ET
P-value, corr.,
activation versus
etanercept treated Symbol Gene product
4.6 0.0144 IL9 interleukin 9
2.6 0.00521 GMCSF human granulocyte-macrophage colony-stimulating factor (CSF1)
2.5 0.00852 LTA lymphotoxin alpha (TNF superfamily, member 1)
2.5 6.37E-05 FEZ1 fasciculation and elongation protein zeta 1 (zygin I)
2.2 0.0069 XCL2 Homo sapiens DNA for SCM-1beta precursor, complete cds
2.1 0.0328 IL4 interleukin 4
1.9 0.00125 HOP homeodomain-only protein
1.8 0.00304 MAOA monoamine oxidase A
1.7 0.0255 IGSF3 immunoglobulin superfamily, member 3
1.7 0.0053 XCL1 chemokine (C motif) ligand 1
1.7 0.0344 LMNA lamin A/C
1.5 0.00736 PTS putative; Homo sapiens PTS gene, complete cds
1.5 0.043 MCM2 MCM2 minichromosome maintenance deficient 2, mitotin (S. cerevisiae)
1.5 0.00033 ACYP1 acylphosphatase 1, erythrocyte (common) type
1.5 0.0274 AF1Q ALL1-fused gene from chromosome 1q
1.5 0.049 IL5 interleukin 5 (colony-stimulating factor, eosinophil)
1.5 0.0391 BATF Homo sapiens B-ATF gene, complete cds
1.5 0.0104 RUVBL2 RuvB-like 2 (E. coli)
1.5 0.0206 PA2G4 proliferation-associated 2G4, 38 kDa
1.4 0.0428 CKS1B CDC28 protein kinase regulatory subunit 1B
1.4 0.0168 UROD uroporphyrinogen decarboxylase
1.4 0.00799 RFC5 replication factor C (activator 1) 5, 36.5 kDa
1.4 0.00401 HIRIP3 HIRA interacting protein 3
1.4 0.0227 ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a isoform 2
1.4 0.0342 RPP30 ribonuclease P (30kD)
1.4 0.0115 ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E
1.4 0.0378 PCCB propionyl coenzyme A carboxylase, beta polypeptide
1.4 0.0331 NPM3 nucleophosmin/nucleoplasmin, 3
1.4 0.00883 PRG2 proteoglycan 2, bone marrow
1.4 0.00961 PSMD1 proteasome (prosome, macropain) 26S subunit, non-ATPase, 1
1.4 0.0388 CDKN3 cyclin-dependent kinase inhibitor 3
1.4 0.0244 RRM1 ribonucleotide reductase M1 polypeptide
1.4 0.0113 NUP155 nucleoporin 155 kDa
1.4 0.00787 SPAG5 sperm associated antigen 5
1.4 0.0455 SNRPA1 small nuclear ribonucleoprotein polypeptide A’
1.4 0.0217 TIMM44 translocase of inner mitochondrial membrane 44 homolog (yeast)
Selected list of genes (out of total 86 genes) downregulated in activated PBMCs as compared to treatment with ET for 24 h. Fold changes are ratios of mean
gene expressions in PBMCs that are activated with anti-CD3/28 as compared to activation in the presence of ET. P-value of ACT versus ET after correction for
multiplicity is listed. Complete list with P-values and fold changes is in Table S1. Gene symbols and products are described in gene ontology annotations.
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like cyclosporine that inhibit T cell cytokine production as
well as T cell proliferation target the calcineurin pathway.
This may suggest that etanercept is regulating some of the
cytokines produced by T cells.
TARC has been shown to be regulated by TNF (Sumyoshi
et al., 2003) and produced by monocytes (Imai et al., 1999)
that are treated with GM-CSF. This may suggest that
etanercept, by reducing the GM-CSF, is inhibiting mono-
cytes that produce TARC in a mixed cell population. Together
with IL-4, -5, and -9, TARC has also been shown to
be upregulated in type 2 diseases like atopic dermatitis
(Jenmalm et al., 2001; Uchida et al., 2002; Klunker et al.,
2003). This suggests that etanercept is affecting cytokines
produced by Th2 T cells.
Comparison of genes regulated by etanercept versus infliximab
We have identified genes suppressed by infliximab using the
same methods as in this study (Haider et al., submitted). Our
comparison with etanercept revealed that most of the genes
regulated by infliximab are unique to that agent (Venn
diagram shown in Figure 3 compares etanercept versus
infliximab-regulated genes). We have listed the top B10
genes in each category of genes unique to effects of each drug
as well as genes that are commonly regulated by the
two inhibitors. A complete list of each category is available
online in supplement Tables S2–S4. The surprising finding in
this comparison is that there are very few commonly
regulated genes by the two inhibitors. Although there
are several cell cycle regulating genes in the list, of particular
interest in the immune response are nuclear basic leucine
zipper transcription factor (BATF) and a negative regulator
of AP-1 activity and 6-pyruvoyltetrahydropterin synthase
(PTS). Basic leucine zipper protein and a negative regulator
of AP-1 activity forms heteromers with Jun proteins
and blocks AP-1 trans-activation in vivo and in vitro.
Overexpression of this gene in mice is known to disrupt the
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Figure 2. Real-time RT-PCR confirmation of genes regulated by etanercept as compared to infliximab: IL-4, -5, -9 (IL-4, -5, and -9), IL-12-receptor b 2, IFN-c,
LTA, and TARC. mRNA from PBMCs activated with anti-CD3/CD28 antibody (ACT) was compared to non-stimulated PBMCs (NS), activation in the presence of
anti-TNF antibodies etanercept or infliximab. Mean of relative mRNA expression normalized to human acidic ribosomal protein is plotted on column bars.
Significance of ACT versus treatment is indicated with asterix (*): n¼6, Po0.01.
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development of thymus-derived natural killer T cells (Wil-
liams et al., 2003); thus, both inhibitors may be regulating the
development of the T cells. Enhanced 6-pyruvoyltetrahy-
dropterin synthase expression is necessary for optimized
tetrahydrobiopterin (BH4) synthesis in IL-1b, and to some
extent TNF and IFN-g-dependent manner. BH4 is an essential
cofactor for nitric oxide synthesis (Franscini et al., 2003). In
human monocytes/macrophages, 6-pyruvoyltetrahydropterin
synthase may be a rate-limiting enzyme in the BH4 synthesis.
We have previously shown that nitric oxide synthase is an
enzyme that is downregulated in skin biopsies of patients
treated with TNF-inhibitor etanercept (Gottlieb et al., 2005).
The suppression of 6-pyruvoyltetrahydropterin synthase
mRNA thus provides a mechanism for reducing expression
of iNOS that could be independent of IFN-g or other
inducers.
It is striking to note that there is a strong signature of type 1
genes regulated by infliximab. We confirmed the mRNA
expressions of IFN-g or IL-12-receptor beta 2 by real-time RT-
PCR (Figure 2). Cytokines such as IFN-g made by Th1 T cells
are important for immune responses to intracellular organ-
isms such as Mycobacterium tuberculosis. Hence, blockade
of TNF by infliximab, which also may result in less synthesis
of IFN-g, could underlie re-activation of tuberculosis which
has been observed in some infliximab-treated patients (Keane
et al., 2001). Conversely, one might postulate that this form of
protective immunity would be less affected in patients treated
with etanercept.
In conclusion, the effects of infliximab are much more
prominent on gene expression of proinflammatory type 1
genes as compared to etanercept. Effects of etanercept may
possibly involve suppression of lymphoid neo-organogenesis.
Potentially, disease improvement in psoriasis or psoriatic
arthritis is mediated by inhibition of ‘‘common’’ inflamma-
tory pathways. The common effects of both inhibitors are on
T cell development and the nitric oxide pathway. This study
describes the pharmacogenomics of the two inhibitors and
elucidates the possible differences observed in the clinical
and safety profiles of these drugs.
MATERIALS AND METHODS
The drawing of blood for these studies was approved by the
Rockefeller University Review Board and volunteers or patients
signed consent for their donation according to the Declaration of
Helsinki Principles.
Samples used in the study
PBMCs were isolated from freshly drawn human blood (in heparin
tube) using Ficoll-Paque Plus according to standard protocol. PBMCs
were resuspended at 1 106/ml in Rosewell Park Memorial Institute,
medium (Invitrogen, Cat No. 21870)þ 10% human serum (Hyclone,
Logan, UT, Cat No. SH30071.03) and PenStrep (Penicillin 10 KU/ml
and Streptomycin 10 mg/ml) – (Invitrogen, Carlsbad, CA, USA, Cat
No. 15140–148). Cultures were set up in 20 ml/dish (100 20 mm,
Corning, Cat No. 25020) in six different experiments for the four
conditions. Non-stimulated PBMCs (NS) served as control to
activation (ACT) with anti-CD3/CD28 using Dynabeadss CD3/
CD28 T Cell Expander (Dynal Biotech, 111.31), activation in the
presence of TNF alpha inhibitors etanercept (Et) (100 mg/ml, Amgen)
and infliximab (I) (100 mg/ml, Centacor,). All reagents were added at
time 0 and cells were collected at 24-hour-post-stimulation.
Floating cells were collected and Dynabeads were removed with
a magnet. An aliquot of at least 500,000 cells was taken to study
phenotype and apoptosis. Adherent cells were lysed with 2 ml/dish
of Qiagen’s RLT buffer (plus 10 ml/ml 2-mercapto-ethanol), and the
lysates were transferred to the corresponding suspended cell pellets,
followed by vortexing and storage at 801C for later RNA
preparation.
Measurement of gene expression in RNA
Target preparation. The microarrays used for this study were
U95Av2-set GeneChip probe arrays (Affymetrix Inc, Santa Clara) that
contain probe sets representing approximately 12,000 genes.
Fragmentation, array hybridization, scanning, and quality con-
trol, GeneChip expression value analysis, hierarchical clustering,
and heatmaps are described in our recent publication (Haider et al.,
2006).
Briefly, for individual transcripts, fold change in expression was
the ratio of the means of expression levels in each condition as
compared to appropriate control (n¼ 6). The heatmap of the
computed tree represent unsupervised hierarchical clustering and
is presented as red and green lines. Each line represents genes with
relative upregulated (red) or downregulated (green) fold changes in
expression values.
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Figure 3. Comparison of effects of etanercept and infliximab on gene
activation. Venn diagram shows comparison of genes regulated by etanercept
(left circle) with genes regulated by infliximab (right circle). Fifty-five genes
are regulated exclusively by etanercept, 513 genes are regulated by infliximab
and both inhibitors commonly regulate 29 genes. Selected list of genes with
fold changes are listed in the figure.
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Statistical comparisons of microarray analysis
To obtain a list with the biologically most interesting genes used in
this study, multiple statistical analyses were performed. Based on the
full data set, one-way analysis of variance was performed to assess
significantly different genes between each condition. Genes with
Po0.05 that passed the Benjamini and Hochberg criterion and fold
change differences of 41.2 between each condition, were further
subjected to paired Welch tests (t-test for unequal variance) to
distinct activation versus non-stimulation and activation versus
etanercept treatment. Owing to the multiple testing problem
encountered in the analysis of microarray data, we chose to declare
those genes with a false discovery rate of at most 5% as having a
significant effect. In this study we considered genes that passed the
Benjamini and Hochberg criterion as biologically most interesting.
Complete lists of genes with P-values and description of relevant
functions of genes are provided in Tables S1–S4.
GeneOntology annotations of differentially expressed genes were
collected from LocusLink (http://www.ncbi.nlm.nih.gov/LocusLink).
Comparison of etanercept-regulated genes with
infliximab-regulated genes
The significantly downregulated genes after treatment with etaner-
cept were further compared to genes that are significantly down-
regulated by infliximab, described elsewhere (Haider et al.
manuscript submitted).
Validation of expression changes with real-time RT-PCR
Analysis of tissue mRNA gene expression
The primers and probes for the TaqMan RT-PCR assays were generated
with the Primer Express algorithm, version 1.0, using published genetic
sequences (NCBI-PubMed) for each gene. Primer sequences were as
follows: IL-4: forward CGACTGCACAGCAGTTCCA, reverse AGG
TTCCTGTCGAGCCGTTT, probe 6-FAM AGGCACAAGCAGCTGA
TCCGATTCC-TAMRA (GenBank accession number NM_000589); IL-
5: forward TGGAGCTGCCTACGTGTATGC, reverse GCAGTGCCAA
GGTCTCTTTCA, probe 6-FAM-CCCCACAGAAATTCCCACAAGT
GCA-TAMRA (GenBank accession number NM_000879); IL-9: forward
GAGCTCCAGTCCGCTGTCA, reverse TGCCACGGAGCACAGGA,
probe 6-FAM-ATGCTTCTGGCCATGGTCCTTACCTCTG-TAMRA (Gen-
Bank accession number NM_000590); IL-12-receptor beta 2: forward
TTATAATCACGTGGCTGTTGATTAAAG, reverse AAATTACATGGGA
AGGCTTCACA, probe 6-FAM-AAATAGATGCGTGCAAGAGAGGCG
ATGTG-TAMA (GenBank accession number NM_001559.2); LTA:
forward TTGGCCTCACACCTTCAGCT, reverse TGCTGTGGGCAA
GATGCA, probe 6-FAM-AGACTGCCCGTCAGCACCCCAA-TAMRA
(GenBank accession number NM_000660); and CC chemokine 17
(TARC): forward GGGCAGGGCCATCTGTTC, reverse TCTCAAGGC
TTTGCAGGTATTTAA, probe 6-FAM-ACCCCAACAACAAGAGAGTGA
AGAATGCA-TAMRA (GenBank accession number NM_002987). The
primer sequences have been published for IFN-g and human acidic
ribosomal protein (Chamian et al., 2005). All primers and probes were
purchased from Applied Biosystems (Foster City, CA). The RT-PCR
reaction was performed using EZ PCR Core Reagents (Applied
Biosystems) according to the manufacturer’s directions. The samples
were amplified and quantified on an Applied Biosystems PRISM 7700
using the following thermal cycler conditions: 2 minutes @ 501C;
30minutes @ 601C; 5minutes @ 951C; and 40 cycles of 15 seconds @
951C followed by 60 seconds @ 601C. Expression of human acidic
ribosomal protein, a housekeeping gene, was used to normalize each
sample and each gene. The data were analyzed and samples quantified
by the software provided with the Applied Biosystems PRISM 7700
(Sequence Detection Systems, ver.1.7).
Statistical analysis of gene expression measured by real-time
RT-PCR
Statistical comparisons of expression level, pair wise activation
versus non-stimulation or activation in the presence of etanercept or
infliximab between each condition were performed using a two-
tailed, Student’s t-test.
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